1. Home
  2. IRWD vs NBTX Comparison

IRWD vs NBTX Comparison

Compare IRWD & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IRWD
  • NBTX
  • Stock Information
  • Founded
  • IRWD 1998
  • NBTX 2003
  • Country
  • IRWD United States
  • NBTX France
  • Employees
  • IRWD N/A
  • NBTX N/A
  • Industry
  • IRWD Biotechnology: Pharmaceutical Preparations
  • NBTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • IRWD Health Care
  • NBTX Health Care
  • Exchange
  • IRWD Nasdaq
  • NBTX Nasdaq
  • Market Cap
  • IRWD 150.9M
  • NBTX 178.7M
  • IPO Year
  • IRWD 2010
  • NBTX 2020
  • Fundamental
  • Price
  • IRWD $0.71
  • NBTX $3.41
  • Analyst Decision
  • IRWD Buy
  • NBTX Strong Buy
  • Analyst Count
  • IRWD 5
  • NBTX 1
  • Target Price
  • IRWD $4.94
  • NBTX $8.00
  • AVG Volume (30 Days)
  • IRWD 4.0M
  • NBTX 7.6K
  • Earning Date
  • IRWD 05-07-2025
  • NBTX 04-02-2025
  • Dividend Yield
  • IRWD N/A
  • NBTX N/A
  • EPS Growth
  • IRWD N/A
  • NBTX N/A
  • EPS
  • IRWD N/A
  • NBTX N/A
  • Revenue
  • IRWD $317,676,000.00
  • NBTX N/A
  • Revenue This Year
  • IRWD N/A
  • NBTX N/A
  • Revenue Next Year
  • IRWD N/A
  • NBTX $221.06
  • P/E Ratio
  • IRWD N/A
  • NBTX N/A
  • Revenue Growth
  • IRWD N/A
  • NBTX N/A
  • 52 Week Low
  • IRWD $0.59
  • NBTX $2.76
  • 52 Week High
  • IRWD $8.23
  • NBTX $7.51
  • Technical
  • Relative Strength Index (RSI)
  • IRWD 30.30
  • NBTX 52.75
  • Support Level
  • IRWD $0.88
  • NBTX $3.26
  • Resistance Level
  • IRWD $0.98
  • NBTX $3.65
  • Average True Range (ATR)
  • IRWD 0.10
  • NBTX 0.19
  • MACD
  • IRWD 0.01
  • NBTX 0.02
  • Stochastic Oscillator
  • IRWD 14.47
  • NBTX 35.00

About IRWD Ironwood Pharmaceuticals Inc.

Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.

About NBTX Nanobiotix S.A.

Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.

Share on Social Networks: